文献速递皮肤肿瘤

皮肤黑色素瘤BRAF、NRAS与TERT启动子突变的临床、环境与组织学分布:563例回顾性研究

Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
PubMed 文献 · Br J Dermatol · 2020-07-21

该回顾性研究分析563例皮肤黑色素瘤患者BRAF、NRAS和TERT启动子突变,发现TERT启动子突变与BRAF或NRAS共现时与更高的肿瘤核分裂率及更差生存相关,且BRAF与TERT共现与日晒部位原发瘤、周围皮肤无慢性日晒损伤及高核分裂率独立相关。

要点

  • TERT启动子突变与BRAF或NRAS共现提示紫外线损伤参与更高且生存更差。
  • BRAF突变与黑色素瘤部位雀斑样痣减少及任何MC1R多态性存在独立相关。
  • BRAF与TERT共现独立关联于日晒部位原发瘤且周围皮肤无慢性日晒损伤。

核心结论

  • TERT启动子突变可区分BRAF与NRAS突变肿瘤,提示更高紫外线损伤参与且黑色素瘤特异性生存更差。

研究设计与样本

  • 回顾性研究纳入563例黑色素瘤患者,检测BRAF、NRAS和TERT启动子体细胞突变。

主要发现

  • TERT启动子突变与BRAF和NRAS共现率分别为26.3%和6.9%。
  • 多因素分析显示BRAF突变独立关联于黑色素瘤部位皮肤雀斑样痣减少及任何MC1R多态性存在增加。
  • TERT启动子突变独立关联于肿瘤核分裂率增加。
  • BRAF与TERT共现独立关联于原发瘤位于通常日晒部位、周围未受累皮肤无组织学慢性日晒损伤及肿瘤核分裂率增加。
  • NRAS与TERT共现独立关联于肿瘤核分裂率增加,且TERT与BRAF或NRAS共现与统计学显著更差生存相关。

临床怎么用

  • 对BRAF或NRAS突变黑色素瘤可考虑检测TERT启动子突变以细化预后分层。

局限性

  • 为回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The distinct somatic mutations that define clinical and histopathological heterogeneity in cutaneous melanoma could be dependent on host susceptibility to exogenous factors like ultraviolet radiation. OBJECTIVES: Firstly, to characterize patients with cutaneous melanoma clinically and pathologically based on the mutational status of BRAF, NRAS and TERT promoter. Secondly, to elucidate the modified features due to the presence of TERT promoter mutations over the background of either BRAF or NRAS mutations. METHODS: We performed a retrospective study on 563 patients with melanoma by investigating somatic mutations in BRAF, NRAS and TERT promoter. RESULTS: We observed co-occurrence of TERT promoter mutations with BRAF and NRAS mutations in 26.3% and 6.9% of melanomas, respectively. Multivariate analysis showed an independent association between BRAF mutations and a decreased presence of cutaneous lentigines at the melanoma site, and an increased association with the presence of any MC1R polymorphism. We also observed an independent association between TERT promoter mutations and increased tumour mitotic rate. Co-occurrence of BRAF and TERT promoter mutations was independently associated with occurrence of primary tumours at usually sun-exposed sites, lack of histological chronic sun damage in surrounding unaffected skin at the melanoma site, and increased tumour mitotic rate. Co-occurrence of NRAS and TERT promoter mutations was independently associated with increased tumour mitotic rate. The presence of TERT promoter together with BRAF or NRAS mutations was associated with statistically significantly worse survival. CONCLUSIONS: The presence of TERT promoter mutations discriminates BRAF- and NRAS-mutated tumours and indicates a higher involvement of ultraviolet-induced damage and tumours with worse melanoma-specific survival than those without any mutation. These observations refine classification of patients with melanoma based on mutational status.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Manrique-Silva E, Rachakonda S, Millán-Esteban D, et al. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients. Br J Dermatol. 2020. PMID: 32506424. doi:10.1111/bjd.19297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。